View by Specialty

Trending

IDC1024Hoberman_graphic
November 04, 2024
4 min read
Save

Q&A: App ‘much better’ than physicians at diagnosing ear infections

Cardiometabolic Disorders News

SPONSORED CONTENT
Save
SPONSORED CONTENT
July 01, 2024
2 min read
Save

Bisphenol A tied to decreased insulin sensitivity for healthy adults

Bisphenol A tied to decreased insulin sensitivity for healthy adults

ORLANDO — Exposure to bisphenol A may lower insulin sensitivity for healthy adults and may lead to higher risk for type 2 diabetes, according to a speaker at the American Diabetes Association Scientific Sessions.

SPONSORED CONTENT
June 29, 2024
2 min read
Save

Workplace sexual harassment associated with higher risk for CVD, type 2 diabetes

Workplace sexual harassment associated with higher risk for CVD, type 2 diabetes

Exposure to workplace sexual harassment was associated with elevated risk for developing CVD and type 2 diabetes, according to a study published in European Journal of Preventive Cardiology.

Trending

IDC1024Hoberman_graphic
November 04, 2024
4 min read
Save

Q&A: App ‘much better’ than physicians at diagnosing ear infections

SPONSORED CONTENT
June 26, 2024
3 min read
Save

SELECT: Semaglutide provides CV benefits for adults with obesity, regardless of HbA1c

SELECT: Semaglutide provides CV benefits for adults with obesity, regardless of HbA1c

ORLANDO — Semaglutide reduces risk for cardiovascular events among adults with overweight or obesity and preexisting cardiovascular disease, regardless of baseline HbA1c or change in HbA1c, according to data from the SELECT trial.

SPONSORED CONTENT
June 25, 2024
2 min read
Save

Wegovy improves functional class in patients with obesity, heart failure at 1 year

Wegovy improves functional class in patients with obesity, heart failure at 1 year

In patients with obesity-driven heart failure with preserved ejection fraction, semaglutide 2.4 mg was associated with more improvement in NYHA functional class compared with placebo, according to new data from the STEP-HFpEF trials.

SPONSORED CONTENT
June 25, 2024
6 min read
Save

Q&A: Petition asks FDA to revise fenofibrate labeling to emphasize no CV outcome benefits

Q&A: Petition asks FDA to revise fenofibrate labeling to emphasize no CV outcome benefits

Because the science underpinning medicine evolves so quickly, it is not uncommon for some doctors to manage patients based on old evidence that is no longer a best practice; this is called clinical inertia.

SPONSORED CONTENT
June 24, 2024
5 min read
Save

Hypercortisolism prevalent among 24% of adults with difficult-to-control type 2 diabetes

Hypercortisolism prevalent among 24% of adults with difficult-to-control type 2 diabetes

ORLANDO — Nearly one-quarter of adults with difficult-to-control type 2 diabetes also have hypercortisolism, and treating hypercortisolism may also benefit glycemic control in those with both conditions, according to speakers.

SPONSORED CONTENT
June 24, 2024
3 min read
Save

FLOW: Semaglutide cuts kidney, cardiovascular, death risks regardless of SGLT2 use

FLOW: Semaglutide cuts kidney, cardiovascular, death risks regardless of SGLT2 use

ORLANDO — Semaglutide use was associated with significant reductions in worsening of kidney disease, cardiovascular events and all-cause death vs. placebo for adults with type 2 diabetes regardless of concomitant use of SGLT2 inhibitors.

SPONSORED CONTENT
June 24, 2024
1 min read
Save

First generic GLP-1 receptor agonist launched

First generic GLP-1 receptor agonist launched

Teva Pharmaceuticals announced it has launched the first generic version of a GLP-1 receptor agonist in the United States, liraglutide 1.8 mg.

SPONSORED CONTENT
June 24, 2024
3 min read
Save

Sex differences in weight loss, not health with semaglutide in heart failure with obesity

Sex differences in weight loss, not health with semaglutide in heart failure with obesity

ORLANDO — Among adults with obesity-related heart failure with preserved ejection fraction, women taking semaglutide lost significantly more weight than men, but greater weight loss did not result in extra health benefits for women vs. men.

SPONSORED CONTENT
June 23, 2024
2 min read
Save

Fenofibrate reduces progression of diabetic eye disease

Fenofibrate reduces progression of diabetic eye disease

ORLANDO — The generic lipid-lowering drug fenofibrate was associated with a significant reduction in progression of diabetic retinopathy and maculopathy, researchers reported.

View more
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails